Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection

References

• Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, et al. Management of helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66:6–30.
   Google Scholar
• Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of helicobacter pylori infection. Am J Gastroenterol. 2017;112(2):212–239. doi:https://doi.org/10.1038/ajg.2016.563.
   Google Scholar
• Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, et al. The toronto consensus for the treatment of helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51–69.e14. doi:https://doi.org/10.1053/j.gastro.2016.04.006.
   Google Scholar
• Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P, et al. Kyoto global consensus report on helicobacter pylori gastritis. Gut. 2015;64(9):1353–1367. doi:https://doi.org/10.1136/gutjnl-2015-309252.
   Google Scholar
• Choi JH, Yang YJ, Bang CS, Lee JJ, Baik GH. Current status of the third-line helicobacter pylori eradication. Gastroenterology Research and Practice. 2018;2018:6523653. doi:https://doi.org/10.1155/2018/6523653.
   Google Scholar
• Kim SG, Jung HK, Lee HL, Jang JY, Lee H, Kim CG, Shin WG, Shin ES, Lee YC. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014;29:1371–1386. doi:https://doi.org/10.1111/jgh.12607.
   Google Scholar
• Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC, et al. Prevalence of primary and secondary antimicrobial resistance of helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013;18(3):206–214. doi:https://doi.org/10.1111/hel.12031.
   Google Scholar
• Kim BJ, Kim HS, Song HJ, Chung I-K, Kim GH, Kim B-W, Shim K-N, Jeon SW, Jung YJ, Yang C-H, et al. Online registry for nationwide database of current trend of helicobacter pylori eradication in Korea: interim analysis. J Korean Med Sci. 2016;31:1246–1253. doi:https://doi.org/10.3346/jkms.2016.31.8.1246.
   Google Scholar
• Gong EJ, Yun SC, Jung HY, Lim H, Choi K-S, Ahn JY, Lee JH, Kim DH, Choi KD, Song HJ, et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci. 2014;29:704–713. doi:https://doi.org/10.3346/jkms.2014.29.5.704.
   Google Scholar
• Lee JH, Ahn JY, Choi KD, Jung H-Y, Kim JM, Baik GH, Kim B-W, Park JC, Jung H-K, Cho SJ, et al. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: a prospective multicenter study. Helicobacter. 2019;24:e12592. doi:https://doi.org/10.1111/hel.12592.
   Google Scholar
• Kim N, Kim JM, Kim CH, Park YS, Lee DH, Kim JS, Jung HC, Song IS. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol. 2006;40(8):683–687. doi:https://doi.org/10.1097/00004836-200609000-00004.
   Google Scholar
• Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, Xiao S, Lu H. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol. 2013;11(802–7.e1). doi:https://doi.org/10.1016/j.cgh.2013.01.008.
   Google Scholar
• Choe JW, Jung SW, Kim SY, Hyun JJ, Jung YK, Koo JS, Yim HJ, Lee SW. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter. 2018;23(2):e12466. doi:https://doi.org/10.1111/hel.12466.
   Google Scholar
• Salmanroghani H, Mirvakili M, Baghbanian M, Salmanroghani R, Sanati G, Yazdian P. Efficacy and tolerability of two quadruple regimens: bismuth, omeprazole, metronidazole with amoxicillin or tetracycline as first-line treatment for eradication of helicobacter pylori in patients with duodenal ulcer: a randomized clinical trial. PLoS One. 2018;13(6):e0197096. doi:https://doi.org/10.1371/journal.pone.0197096.
   Google Scholar
• Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, Lu H. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut. 2015;64(11):1715–1720. doi:https://doi.org/10.1136/gutjnl-2015-309900.
   Google Scholar
• Chen Q, Zhang W, Fu Q, Liang X, Liu W, Xiao S, Lu H. Rescue therapy for helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in Bismuth quadruple therapy. Am J Gastroenterol. 2016;111:1736–1742. doi:https://doi.org/10.1038/ajg.2016.443.
   Google Scholar
• Lim H, Bang CS, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, et al. Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial. Medicine (Baltimore). 2018;97(46):e13245. doi:https://doi.org/10.1097/MD.0000000000013245.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; seventeenth informational supplement. [accessed 2018 Sep 13]. http://www.microbiolab-bg.com/CLSI.pdf.
   Google Scholar
• Chung J-W, Lee JH, Jung H-Y, Yun S-C, Oh T-H, Choi KD, Song HJ, Lee GH, Kim J-H. Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter. 2011;16(4):289–294. doi:https://doi.org/10.1111/j.1523-5378.2011.00844.x.
   Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174. doi:https://doi.org/10.2307/2529310.
   Google Scholar
• Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the eradication of helicobacter pylori. Am J Ther. 2017;24:e751–e757. doi:https://doi.org/10.1097/MJT.0000000000000389.
   Google Scholar
• Marcus EA, Sachs G, Scott DR. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics. Aliment Pharmacol Ther. 2015;42:922–933. doi:https://doi.org/10.1111/apt.13346.
   Google Scholar
• Graham DY, Lee SY. How to effectively use Bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am. 2015;44:537–563. doi:https://doi.org/10.1016/j.gtc.2015.05.003.
   Google Scholar
• Sugimoto M, Shirai N, Nishino M, Kodaira C, Uotani T, Yamade M, Sahara S, Ichikawa H, Sugimoto K, Miyajima H, et al. Rabeprazole 10 mg q.d.s. decreases 24-h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype. Aliment Pharmacol Ther. 2012;36:627–634. doi:https://doi.org/10.1111/apt.12014.
   Google Scholar
• Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res. 2016;5:pii: F1000 Faculty Rev-1747. doi:https://doi.org/10.12688/f1000research.8598.1.
   Google Scholar
• Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65(9):1439–1446. doi:https://doi.org/10.1136/gutjnl-2015-311304.
   Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59:1143–1153. doi:https://doi.org/10.1136/gut.2009.192757.
   Google Scholar
• Van der Wouden EJ, Thijs JC, Zwet AA. The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Aliment Pharmacol Ther. 1999;13:297–302. doi:https://doi.org/10.1046/j.1365-2036.1999.00486.x.
   Google Scholar
• Chi CH, Lin CY, Sheu BS, Yang H-B, Huang A-H, Wu -J-J. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther. 2003;18:347–353. doi:https://doi.org/10.1046/j.1365-2036.2003.01653.x.
   Google Scholar
• Uygun A, Ozel AM, Yildiz O, Aslan M, Yesilova Z, Erdil A, Bagci S, Gunhan O. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol. 2008;23:42–45. doi:https://doi.org/10.1111/j.1440-1746.2007.04984.x.
   Google Scholar
• Yu L, Luo L, Long X, Liang X, Ji Y, Graham DY, Lu H. High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: A randomized trial. Helicobacter. 2019;24:e12596. doi:https://doi.org/10.1111/hel.12596.
   Google Scholar
• Luo L, Ji Y, Yu L, Huang Y, Liang X, Graham DY, Lu H. 14-day high-dose amoxicillin- and metronidazole-containing triple therapy with or without Bismuth as first-line helicobacter pylori treatment. Dig Dis Sci. 2020. doi:https://doi.org/10.1007/s10620-020-06115-7.
   Google Scholar
• Kwack W, Lim Y, Lim C, Graham DY. High dose ilaprazole/amoxicillin as first-line regimen for helicobacter pylori infection in Korea. Gastroenterol Res Pract. 2016;2016:1648047. doi:https://doi.org/10.1155/2016/1648047.
   Google Scholar
• Park HY, Kang EJ, Kim DG, Kim KJ, Choi JW, Nam SY, Kwon YH, Lee HS, Jeon SW. High and frequent dose of dexlansoprazole and amoxicillin dual therapy for helicobacter pylori infections: a single arm prospective study. Korean J Gastroenterol. 2017;70:176–180. doi:https://doi.org/10.4166/kjg.2017.70.4.176.
   Google Scholar
• Bang CS, Kim YS, Park SH, Kim JB, Baik GH, Suk KT, Yoon JH, Kim DJ. Additive effect of pronase on the eradication rate of first-line therapy for helicobacter pylori infection. Gut Liver. 2015;9(3):340–345. doi:https://doi.org/10.5009/gnl13399.
   Google Scholar
• Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol. 2002;53:163–171. doi:https://doi.org/10.1046/j.0306-5251.2001.01531.x.
   Google Scholar
• Arslan N, Yilmaz O, Demiray-Gurbuz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol. 2017;23:2854–2869. doi:https://doi.org/10.3748/wjg.v23.i16.2854.
   Google Scholar